pre-IPO PHARMA

COMPANY OVERVIEW

Metabomed is a drug discovery company in the field of cancer metabolism. Through its proprietary technology, Metabomed identifies metabolic pathways that arise uniquely in cancers and are essential for their growth. These discoveries are used to develop small molecules that specifically target the reprogrammed cancer cells' metabolism to halt their growth. Since these molecules inhibit divergent pathways that are specific to cancer cells, these therapies will not damage healthy surrounding tissues.


LOCATION

  • Yavne, , Israel

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.metabomed.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    arkin-bio-ventures boehringer-ingelheim-venture-fund m-ventures pfizer-ventures pontifax techion


    PRESS RELEASES


    Sep 9, 2020

    MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer English English


    Dec 19, 2019

    Metabomed Completes a $12.5 Million Raise in Order to Advance Its Lead Program Into Clinical Studies


    Apr 5, 2016

    Krebszellenstoffwechselunternehmen Metabomed schließt 18 Mio. US-Dollar schwere Serie-A-Finanzierungsrunde ab


    Apr 4, 2016

    Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing


    For More Press Releases


    Google Analytics Alternative